All In Biotech

Drug Trial Radar · NCT07497074

JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer

A Phase II Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Combination With Platinum-Based Chemotherapy With or Without Bevacizumab in Patients With Advanced Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Apr 2026

Primary completion

Oct 2027

Study completion Jun 2028

Sponsor

Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if the therapy of JSKN033 plus chemotherapy with or with bevacizumab is safe to treat patients with advanced cervical cancer. It will also learn about the antitumor activity and pharmacokinetic/ pharmacodynamic profiles of this therapy.

Conditions

  • Cervical Cancer

Interventions

  • JSKN033Drug

    JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

  • PlatinumDrug

    JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

  • BevacizumabDrug

    JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab at selected dose levels according to protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: 21 days from the first dose
  2. Frequency and severity of Treatment-Related Adverse Events (TRAEs)Time frame: 21 days from the first dose
  3. Frequency and severity of Serious Adverse Events (SAEs)Time frame: 21 days from the first dose
  4. Objective Response Rate (ORR) as assessed by the investigator and IRC per RECIST 1.1.Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 12 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.